Wednesday, 11 February 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 11 February 2026
News

Sanofi drug spurs law change

Posted 11 February 2026 AM

Sanofi’s Beyfortus could trigger a change in how new and emerging therapies are subsidised in Australia, with a bill introduced to expand the definition of ‘vaccine’ under the National Health Act 1953.

It comes after the PBAC deferred making a recommendation in May 2025 to list Beyfortus on the National Immunisation Program (NIP) for the prevention of RSV lower respiratory tract disease in neonates and infants born during or entering their first RSV season; and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (14)

Access & Reimbursement (1)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (6)

Other (19)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.